- JP-listed companies
- StemCell Institute Inc.
- Income statement
StemCell Institute Inc. (7096) Income statement
Market cap
¥6.9B
P/E ratio
65.2x
Stemcell Research Institute stores umbilical cord blood and tissue for expecting families, preserving stem cells for potential future medical treatments.
| 2016/03 | 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | 2026/03 | |
| Revenue | 755 | 807 | 862 | 1,150 | 1,676 | 1,410 | 1,782 | 2,091 | 2,481 | 2,679 | 2,811 |
| Revenue growth (%) | - | ||||||||||
| Cost of revenue | - | - | - | 389 | 544 | 485 | 671 | 755 | 905 | 987 | 1,099 |
| Gross profit | - | - | - | 761 | 1,133 | 924 | 1,111 | 1,336 | 1,576 | 1,692 | 1,712 |
| Gross margin (%) | - | - | - | ||||||||
| Operating margin (%) | - | - | - | ||||||||
| Operating expenses | - | - | - | 545 | 750 | 837 | 884 | 1,038 | 1,162 | 1,274 | 1,510 |
| Operating income | - | - | - | 216 | 382 | 87 | 227 | 298 | 414 | 419 | 202 |
| Income before tax | 187 | 162 | 111 | 216 | 383 | 92 | 213 | 300 | 417 | 429 | 217 |
| Pretax margin (%) | 24.8 | 20.1 | 12.9 | 18.8 | 22.8 | 6.6 | 11.9 | 14.4 | 16.8 | 16 | 7.7 |
| Provision for income taxes | - | - | - | 72 | 105 | 29 | 79 | 81 | 130 | 180 | 87 |
| Effective tax rate (%) | - | - | - | ||||||||
| Net income | 119 | 108 | 70 | 143 | 277 | 62 | 134 | 198 | 311 | 386 | 156 |
| Earnings per share | 17,162.33 | 15,509.97 | 10,002.6 | 29.35 | 57.01 | 12.81 | 26.41 | 19.33 | 30.35 | 37.67 | 15.44 |
| Dividend per share | - | - | - | - | - | - | - | - | - | 25 | - |